Only a fraction of the materials employed in the preparation of a typical active pharmaceutical ingredient (API) is incorporated into the final product. In particular, solvents are estimated to contribute 56 percent of the total material used to make an API, and this statistic is most acutely felt in the area of peptide synthesis. Increasing regulatory, financial and political pressures have led manufacturers to focus on the sustainability credentials of any synthetic procedure.
In this free webinar, the featured speaker will discuss current efforts in the peptide chemistry community towards pursuing more sustainable replacement solvents for peptide synthesis, as well as other considerations such as coupling chemistry.
Craig Jamieson, PhD, Senior Lecturer, University of Strathclyde, Glasgow, UK
Craig Jamieson earned his BSc (Hons) in Chemistry at the University of Glasgow in 1996. His PhD studies were carried out under the direction of Professor R Ramage at the University of Edinburgh (1999). Following postdoctoral research under the supervision of Professor S V Ley at the University of Cambridge, in 2001 he was appointed as a Principal Scientist in GlaxoSmithKline’s Discovery Medicinal Chemistry group working on a range of exploratory medicinal chemistry programmes. In 2004, Dr. Jamieson joined Organon Laboratories (later Merck Research Labs) as a Group Leader in the Medicinal Chemistry Department, with responsibility for hit to clinical candidate optimisation. In August 2010, he was appointed as a John Anderson Research Lecturer in Chemical Biology, based in the Department of Pure and Applied Chemistry at the University of Strathclyde.
A major area of the Jamieson Group’s focus for research continues to be in the Chemistry-Biology-Medicine continuum. In this regard, Dr. Jamieson has a number of active programmes centred around hit and lead identification on disease targets and mechanisms in areas of significant societal need, particularly in diseases of ageing. Allied to their work in the medicinal chemistry sphere, the Jamieson Group also has a keen interest in the development of novel, enabling synthetic methodologies to enhance the armamentarium of molecule makers working in their arena.
Who Should Attend?
Professionals focused on:
- Peptide chemistry
- Understanding how replacement solvents and coupling chemistry impact peptide synthesis
- Scientist II and higher involved with Peptide chemistry
- Director, peptide therapeutics
What You Will Learn
Participants will gain insights into:
- Overview of peptide chemistry
- API preparation
- Sustainable replacement solvents for peptide synthesis
- Coupling chemistry
Gyros Protein Technologies
Gyros Protein Technologies enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.